Premium
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega‐3 fatty acids
Author(s) -
Musolino Antonino,
Panebianco Michele,
Zendri Enrico,
Santini Marcello,
Di Nuzzo Sergio,
Ardizzoni Andrea
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07596.x
Subject(s) - bexarotene , fenofibrate , medicine , cutaneous t cell lymphoma , hypertriglyceridemia , refractory (planetary science) , concomitant , mycosis fungoides , cholesterol , endocrinology , gastroenterology , pharmacology , lymphoma , chemistry , triglyceride , biochemistry , biology , nuclear receptor , astrobiology , transcription factor , gene
Summary Bexarotene is approved for the treatment of cutaneous T cell lymphomas in patients refractory to at least one prior systemic therapy. Associated hypertriglyceridaemia requires monitoring, but can readily be managed with concomitant medication, such as fenofibrate. Here we report three cases of hypertriglyceridaemia secondary to bexarotene assumption, which was adequately managed with omega‐3 fatty acids. If fenofibate‐related side effects occur, or a statin is required to control low‐density lipoprotein‐cholesterol, omega‐3 fatty acids should be considered as a good alternative therapy to lower lipid levels during bexarotene treatment.